Further evidence for sustained systemic inflammation in xenograft recipients (SIXR)

Xenotransplantation

Volumn 22, Issue 5, 2015, Pages 399-405

  Iwase, Hayato ^a   Ekser, Burcin ^a,b,g   Zhou, Huidong ^a,c   Liu, Hong ^d   Satyananda, Vikas ^a   Humar, Rishab ^a   Humar, Pooja ^a   Hara, Hidetaka ^a   Long, Cassandra ^a   Bhama, Jay K ^e   Bajona, Pietro ^a   Wang, Yi ^c   Wijkstrom, Martin ^a   Ayares, David ^f   Ezzelarab, Mohamed B ^a   Cooper, David K C ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF SOUTH CHINA   (China)

^d Medical University   (China)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f REVIVICOR INC   (United States)

^g INDIANA UNIVERSITY   (United States)

Author keywords

baboons; C reactive protein; coagulation; D dimer; genetically engineered; IL 6R blockade; inflammation; pigs; platelets; xenotransplantation

Indexed keywords

C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; INTERLEUKIN 6 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY GRAFT; ARTICLE; BABOON; CONTROLLED STUDY; GENETIC ENGINEERING; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; INFLAMMATION; NONHUMAN; PIG; PRIORITY JOURNAL; SUSTAINED SYSTEMIC INFLAMMATION; T LYMPHOCYTE; THROMBOCYTOPENIA; XENOGRAFT; ANIMAL; ARTERY; EVALUATION STUDY; GRAFT REJECTION; IMMUNOLOGY; POSTOPERATIVE COMPLICATIONS; TRANSGENIC ANIMAL; TRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARTERIES; GRAFT REJECTION; HEART TRANSPLANTATION; INFLAMMATION; PAPIO; POSTOPERATIVE COMPLICATIONS; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84941941268     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12182     Document Type: Article

References (42)

1. Ekser B, Ezzelarab M, Hara H, et al., Clinical xenotransplantation: the next medical revolution? Lancet 2012; 379: 672-683.
2. Ezzelarab M, Ekser B, Azimzadeh A, et al., Systemic inflammation in xenograft recipients precedes activation of coagulation. Xenotransplantation 2015; 22: 32-47.
3. Ezzelarab M, Garcia B, Azimzadeh A, et al., The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients. Transplantation 2009; 87: 805-812.
4. Houser SL, Kuwaki K, Knosalla C, et al., Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons. Xenotransplantation 2004; 11: 416-425.
5. Kozlowski T, Shimizu A, Lambrigts D, et al., Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption. Transplantation 1999; 67: 18-30.
6. Kuwaki K, Knosalla C, Dor FJ, et al., Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am J Transplant 2004; 4: 363-372.
7. Kuwaki K, Tseng YL, Dor FJ, et al., Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11: 29-31.
8. Lin CC, Ezzelarab M, Shapiro R, et al., Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation. Am J Transplant 2010; 10: 1556-1568.
9. Shimizu A, Hisashi Y, Kuwaki K, et al., Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008; 172: 1471-1481.
10. Barrett TD, Hennan JK, Marks RM, Lucchesi BR,. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther 2002; 303: 1007-1013.
11. Ezzelarab MB, Ekser B, Echeverri G, et al., Costimulation blockade in pig artery patch xenotransplantation- A simple model to monitor the adaptive immune response in nonhuman primates. Xenotransplantation 2012; 19: 221-232.
12. Iwase H, Ekser B, Satyananda V, et al., Pig-to-baboon heterotopic heart transplantation-exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens. Xenotransplantation 2015; 22: 211-220.
13. Cozzi E, White DJ,. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1: 964-966.
14. Loveland BE, Milland J, Kyriakou P, et al., Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons. Xenotransplantation 2004; 11: 171-183.
15. Phelps CJ, Koike C, Vaught TD, et al., Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411-414.
16. Iwase H, Ekser B, Satyananda V, et al., Initial in vivo experience of pig artery patch transplantation in baboons using mutant MHC (CIITA-DN) pigs. Transpl Immunol 2015; 32: 99-108.
17. Ayares D, Phelps C, Vaught TD, et al., Genetic engineering of source pigs for xenotransplantation: progress and prospects. Xenotransplantation 2013; 20: 361 (Abstract #408).
18. Hara H, Witt W, Crossley T, et al., Human dominant-negative class II transactivator transgenic pigs-effect on the human anti-pig T-cell immune response and immune status. Immunology 2013; 140: 39-46.
19. Marco MR, Dons EM, Van Der Windt DJ, et al., Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys. Transpl Immunol 2013; 29: 88-98.
20. Cooper DK, Ye Y, Niekrasz M,. Heart transplantation in primates. In:, Cramer DVPL, Makowka L, eds. Handbook of Animal Models in Transplantation Research. Boca Raton: CRC Press, 1994: p. 173.
21. Wu G, Chai N, Kim I, Klein AS, Jordan SC,. Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization. Transpl Immunol 2013; 28: 138-143.
22. Buhler L, Basker M, Alwayn IP, et al., Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. Transplantation 2000; 70: 1323-1331.
23. Cowan PJ, Aminian A, Barlow H, et al., Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 2000; 69: 2504-2515.
24. Meyer C, Wolf P, Romain N, et al., Use of von Willebrand diseased kidney as donor in a pig-to-primate model of xenotransplantation. Transplantation 1999; 67: 38-45.
25. Wu G, Pfeiffer S, Schroder C, et al., Coagulation cascade activation triggers early failure of pig hearts expressing human complement regulatory genes. Xenotransplantation 2007; 14: 34-47.
26. Fareed J, Hoppensteadt DA, Leya F, et al., Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 1998; 44: 1845-1853.
27. Kim I, Wu G, Chai NN, Klein AS, Jordan S,. Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization. Transplantation 2014; 98: 1262-1270.
28. Delvaeye M, Conway EM,. Coagulation and innate immune responses: can we view them separately? Blood 2009; 114: 2367-2374.
29. Esmon CT,. Coagulation and inflammation. J Endotoxin Res 2003; 9: 192-198.
30. Esmon CT,. Inflammation and thrombosis. J Thromb Haemost 2003; 1: 1343-1348.
31. Esmon CT, Xu J, Lupu F,. Innate immunity and coagulation. J Thromb Haemost 2011; 9 (Suppl. 1): 182-188.
32. Wen D, Du X, Dong JZ, Zhou XL, Ma CS,. Value of D-dimer and C reactive protein in predicting inhospital death in acute aortic dissection. Heart 2013; 99: 1192-1197.
33. Bucek RA, Reiter M, Quehenberger P, Minar E,. C-reactive protein in the diagnosis of deep vein thrombosis. Br J Haematol 2002; 119: 385-389.
34. Naeem MA, Usman M, Latif MK, Aamir M,. The relationship of D-dimer levels with risk for developing deep-vein thrombosis and/or pulmonary thromboembolism after orthopaedic trauma surgery. J Ayub Med Coll Abbottabad 2009; 21: 113-116.
35. Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM,. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001; 21: 603-610.
36. Pai JK, Pischon T, Ma J, et al., Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-2610.
37. Ridker PM, Cannon CP, Morrow D, et al., C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
38. Edgington TS, Curtiss LK, Plow EF,. A linkage between the hemostatic and immune systems embodied in the fibrinolytic release of lymphocyte suppressive peptides. J Immunol 1985; 134: 471-477.
39. Gauldie J, Northemann W, Fey GH,. IL-6 functions as an exocrine hormone in inflammation. Hepatocytes undergoing acute phase responses require exogenous IL-6. J Immunol 1990; 144: 3804-3808.
40. Ritchie DG, Levy BA, Adams MA, Fuller GM,. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. Proc Natl Acad Sci U S A 1982; 79: 1530-1534.
41. Robson SC, Shephard EG, Kirsch RE,. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322-326.
42. Bari SF, Khan A, Lawson T,. C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. BMJ Case Rep 2013; doi: 10.1136/bcr-2013-010423.